• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ZLD
Click for more information
8.77% 62.0¢

ZELIRA THERAPEUTICS LIMITED - Announcements

Market Cap $7.716M  ! watchlist Created with Sketch. Add to my watchlist

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company... Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
ZLD Zelda Partners with Ilera HealthCarePRICE SENSITIVE12/03/19
ZLD Aus Patent For Novel Prognostic Marker for Breast CancerPRICE SENSITIVE06/03/19
ZLD Novel Cannabis Pathway for Treatment of Breast Cancer28/02/19
ZLD Appendix 4D & FY19 Interim Financial ReportPRICE SENSITIVE22/02/19
ZLD Appendix 3B19/02/19
ZLD Results of Meeting18/02/19
ZLD ZLD Engages ICCI for Clinical Trial and Regulatory Expertise12/02/19
ZLD Change of Director's Interest Notice05/02/19
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/01/19
ZLD December 2018 Quarterly Report and Board TransitionPRICE SENSITIVE30/01/19
ZLD Notice of General Meeting18/01/19
ZLD Appendix 3B16/01/19
ZLD Response to ASX Appendix 3Y Query16/01/19
ZLD Change in substantial holding14/01/19
ZLD Change of Director's Interest Notice14/01/19
ZLD Response to ASX Price and Volume QueryPRICE SENSITIVE08/01/19
ZLD Change of Director's Interest Notice14/12/18
ZLD Change of Director's Interest Notice07/12/18
ZLD ZLD to Invest in Development of Oral Spray FormulationsPRICE SENSITIVE06/12/18
ZLD SUD: SUDA Enters Agreement To Develop Cannabinoid SprayPRICE SENSITIVE06/12/18
ZLD Results of Meeting30/11/18
ZLD Annual General Meeting Presentation 201830/11/18
ZLD Investor Presentation - Non-deal Roadshow27/11/18
ZLD Opioid reduction clinical trial with St Vincent's HospitalPRICE SENSITIVE26/11/18
ZLD Appendix 3B22/11/18
ZLD Correction to Unlisted Option Expiry Date14/11/18
ZLD Release From Escrow and Founders Commitment Not to Sell07/11/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/10/18
ZLD September 2018 Quarterly ReportPRICE SENSITIVE31/10/18
ZLD Notice of Annual General Meeting29/10/18
ZLD Managing Director Remuneration Variation12/10/18
ZLD Zelda Focuses Clinical Trial ActivityPRICE SENSITIVE11/10/18
ZLD US Autism Observational Study UnderwayPRICE SENSITIVE10/10/18
ZLD First Patient Dosed in Zelda Insomnia TrialPRICE SENSITIVE26/09/18
ZLD Investor Presentation - Non-deal Roadshow25/09/18
ZLD Zelda Forms New Partnership to Access German MarketPRICE SENSITIVE04/09/18
ZLD Appendix 4G31/08/18
ZLD Appendix 4E & Financial StatementsPRICE SENSITIVE31/08/18
ZLD Appendix 3B22/08/18
ZLD Two Key Clinical Appointments to Medical Advisory Board22/08/18
ZLD June 2018 Quarterly ReportPRICE SENSITIVE30/07/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/07/18
ZLD Initial Director's Interest Notice16/07/18
ZLD Commencement of New Managing DirectorPRICE SENSITIVE16/07/18
ZLD Paediatric Brain Cancer Research Update06/06/18
ZLD Details of Company Address25/05/18
ZLD Appointment of Managing DirectorPRICE SENSITIVE22/05/18
ZLD March 2018 Quarterly ReportPRICE SENSITIVE30/04/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
ZLD Insomnia Clinical Trial Update-Patient Recruitment CompletedPRICE SENSITIVE23/04/18
ZLD Research into Cannabinoids and Diabetes-Related Conditions18/04/18
ZLD US Autism Observational Study Receives IRB Approval13/04/18
ZLD Expansion of Pancreatic Cancer Research ProgrammePRICE SENSITIVE06/03/18
ZLD Appendix 4D & FY18 Interim Financial ReportPRICE SENSITIVE27/02/18
ZLD December 2017 Quarterly Report31/01/18
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
ZLD Shares Begin Trading in the USA on the OTCQB Venture Market22/01/18
ZLD Appendix 3B12/01/18
ZLD Cancellation of Unlisted Options10/01/18
ZLD Change of Director's Interest Notice20/12/17
ZLD Zelda joins with US Children's Hospital for autism studyPRICE SENSITIVE11/12/17
ZLD Trading HaltPRICE SENSITIVE08/12/17
ZLD Response to ASX Aware QueryPRICE SENSITIVE05/12/17
ZLD Australian Regulators Approve Zelda Insomnia Clinical TrialPRICE SENSITIVE29/11/17
ZLD Results of Meeting24/11/17
ZLD Annual General Meeting Presentation 201724/11/17
ZLD Chairman's Address - Annual General Meeting24/11/17
ZLD Response to ASX Price and Volume QueryPRICE SENSITIVE22/11/17
ZLD Trading HaltPRICE SENSITIVE21/11/17
ZLD Appendix 3B - Release of Securities from Escrow16/11/17
ZLD Release from Escrow01/11/17
ZLD September 2017 Quarterly Report31/10/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
ZLD Notice of Annual General Meeting26/10/17
ZLD Successful Results in Autism Observation TrialPRICE SENSITIVE18/09/17
ZLD Update on Closing Date of CannPal Priority Offer18/09/17
ZLD Update on Research Programme in Chile13/09/17
ZLD Appendix 4G31/08/17
ZLD Appendix 4E & Financial StatementsPRICE SENSITIVE31/08/17
ZLD CannPal Priority Share Offer Clarification Announcement31/08/17
ZLD Priority Share Offer for CannPal IPO Shares29/08/17
ZLD Company Presentation on 2017 Half Year Activities25/08/17
ZLD Expansion of Breast Cancer Research CollaborationPRICE SENSITIVE31/07/17
ZLD June 2017 Quarterly Report28/07/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE28/07/17
ZLD ENT:Acquisition of prospective Au& Cu/Zn Murchison TenementsPRICE SENSITIVE26/07/17
ZLD Updated Securities Trading and Corporate Governance Policies30/06/17
ZLD Zelda Enters into Strategic Agreement with Knop LaboratoriesPRICE SENSITIVE15/06/17
ZLD Positive Results From Pre-Clinical Breast Cancer StudiesPRICE SENSITIVE02/06/17
ZLD March 2017 Quarterly ReportPRICE SENSITIVE28/04/17
ZLD Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
ZLD Appendix 3B - Release of Securities from Escrow21/04/17
ZLD Clinical Research Programme to Expand to Include AutismPRICE SENSITIVE19/04/17
ZLD Change in substantial holding x 306/04/17
ZLD Appendix 3B05/04/17
ZLD Release from Escrow04/04/17
ZLD Cleansing ProspectusPRICE SENSITIVE03/04/17
ZLD Zelda Successfully Completes Capital RaisingPRICE SENSITIVE30/03/17
ZLD Trading HaltPRICE SENSITIVE28/03/17
ZLD Zelda Enters Strategic Partnership with CannPalPRICE SENSITIVE27/03/17
ZLD Zelda Partners with Ilera HealthCare
12/03/19PRICE SENSITIVE
ZLD Aus Patent For Novel Prognostic Marker for Breast Cancer
06/03/19PRICE SENSITIVE
ZLD Novel Cannabis Pathway for Treatment of Breast Cancer
28/02/19
ZLD Appendix 4D & FY19 Interim Financial Report
22/02/19PRICE SENSITIVE
ZLD Appendix 3B
19/02/19
ZLD Results of Meeting
18/02/19
ZLD ZLD Engages ICCI for Clinical Trial and Regulatory Expertise
12/02/19
ZLD Change of Director's Interest Notice
05/02/19
ZLD Appendix 4C - quarterly
30/01/19PRICE SENSITIVE
ZLD December 2018 Quarterly Report and Board Transition
30/01/19PRICE SENSITIVE
ZLD Notice of General Meeting
18/01/19
ZLD Appendix 3B
16/01/19
ZLD Response to ASX Appendix 3Y Query
16/01/19
ZLD Change in substantial holding
14/01/19
ZLD Change of Director's Interest Notice
14/01/19
ZLD Response to ASX Price and Volume Query
08/01/19PRICE SENSITIVE
ZLD Change of Director's Interest Notice
14/12/18
ZLD Change of Director's Interest Notice
07/12/18
ZLD ZLD to Invest in Development of Oral Spray Formulations
06/12/18PRICE SENSITIVE
ZLD SUD: SUDA Enters Agreement To Develop Cannabinoid Spray
06/12/18PRICE SENSITIVE
ZLD Results of Meeting
30/11/18
ZLD Annual General Meeting Presentation 2018
30/11/18
ZLD Investor Presentation - Non-deal Roadshow
27/11/18
ZLD Opioid reduction clinical trial with St Vincent's Hospital
26/11/18PRICE SENSITIVE
ZLD Appendix 3B
22/11/18
ZLD Correction to Unlisted Option Expiry Date
14/11/18
ZLD Release From Escrow and Founders Commitment Not to Sell
07/11/18
ZLD Appendix 4C - quarterly
31/10/18PRICE SENSITIVE
ZLD September 2018 Quarterly Report
31/10/18PRICE SENSITIVE
ZLD Notice of Annual General Meeting
29/10/18
ZLD Managing Director Remuneration Variation
12/10/18
ZLD Zelda Focuses Clinical Trial Activity
11/10/18PRICE SENSITIVE
ZLD US Autism Observational Study Underway
10/10/18PRICE SENSITIVE
ZLD First Patient Dosed in Zelda Insomnia Trial
26/09/18PRICE SENSITIVE
ZLD Investor Presentation - Non-deal Roadshow
25/09/18
ZLD Zelda Forms New Partnership to Access German Market
04/09/18PRICE SENSITIVE
ZLD Appendix 4G
31/08/18
ZLD Appendix 4E & Financial Statements
31/08/18PRICE SENSITIVE
ZLD Appendix 3B
22/08/18
ZLD Two Key Clinical Appointments to Medical Advisory Board
22/08/18
ZLD June 2018 Quarterly Report
30/07/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
30/07/18PRICE SENSITIVE
ZLD Initial Director's Interest Notice
16/07/18
ZLD Commencement of New Managing Director
16/07/18PRICE SENSITIVE
ZLD Paediatric Brain Cancer Research Update
06/06/18
ZLD Details of Company Address
25/05/18
ZLD Appointment of Managing Director
22/05/18PRICE SENSITIVE
ZLD March 2018 Quarterly Report
30/04/18PRICE SENSITIVE
ZLD Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
ZLD Insomnia Clinical Trial Update-Patient Recruitment Completed
23/04/18PRICE SENSITIVE
ZLD Research into Cannabinoids and Diabetes-Related Conditions
18/04/18
ZLD US Autism Observational Study Receives IRB Approval
13/04/18
ZLD Expansion of Pancreatic Cancer Research Programme
06/03/18PRICE SENSITIVE
ZLD Appendix 4D & FY18 Interim Financial Report
27/02/18PRICE SENSITIVE
ZLD December 2017 Quarterly Report
31/01/18
ZLD Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
ZLD Shares Begin Trading in the USA on the OTCQB Venture Market
22/01/18
ZLD Appendix 3B
12/01/18
ZLD Cancellation of Unlisted Options
10/01/18
ZLD Change of Director's Interest Notice
20/12/17
ZLD Zelda joins with US Children's Hospital for autism study
11/12/17PRICE SENSITIVE
ZLD Trading Halt
08/12/17PRICE SENSITIVE
ZLD Response to ASX Aware Query
05/12/17PRICE SENSITIVE
ZLD Australian Regulators Approve Zelda Insomnia Clinical Trial
29/11/17PRICE SENSITIVE
ZLD Results of Meeting
24/11/17
ZLD Annual General Meeting Presentation 2017
24/11/17
ZLD Chairman's Address - Annual General Meeting
24/11/17
ZLD Response to ASX Price and Volume Query
22/11/17PRICE SENSITIVE
ZLD Trading Halt
21/11/17PRICE SENSITIVE
ZLD Appendix 3B - Release of Securities from Escrow
16/11/17
ZLD Release from Escrow
01/11/17
ZLD September 2017 Quarterly Report
31/10/17
ZLD Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
ZLD Notice of Annual General Meeting
26/10/17
ZLD Successful Results in Autism Observation Trial
18/09/17PRICE SENSITIVE
ZLD Update on Closing Date of CannPal Priority Offer
18/09/17
ZLD Update on Research Programme in Chile
13/09/17
ZLD Appendix 4G
31/08/17
ZLD Appendix 4E & Financial Statements
31/08/17PRICE SENSITIVE
ZLD CannPal Priority Share Offer Clarification Announcement
31/08/17
ZLD Priority Share Offer for CannPal IPO Shares
29/08/17
ZLD Company Presentation on 2017 Half Year Activities
25/08/17
ZLD Expansion of Breast Cancer Research Collaboration
31/07/17PRICE SENSITIVE
ZLD June 2017 Quarterly Report
28/07/17
ZLD Appendix 4C - quarterly
28/07/17PRICE SENSITIVE
ZLD ENT:Acquisition of prospective Au& Cu/Zn Murchison Tenements
26/07/17PRICE SENSITIVE
ZLD Updated Securities Trading and Corporate Governance Policies
30/06/17
ZLD Zelda Enters into Strategic Agreement with Knop Laboratories
15/06/17PRICE SENSITIVE
ZLD Positive Results From Pre-Clinical Breast Cancer Studies
02/06/17PRICE SENSITIVE
ZLD March 2017 Quarterly Report
28/04/17PRICE SENSITIVE
ZLD Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
ZLD Appendix 3B - Release of Securities from Escrow
21/04/17
ZLD Clinical Research Programme to Expand to Include Autism
19/04/17PRICE SENSITIVE
ZLD Change in substantial holding x 3
06/04/17
ZLD Appendix 3B
05/04/17
ZLD Release from Escrow
04/04/17
ZLD Cleansing Prospectus
03/04/17PRICE SENSITIVE
ZLD Zelda Successfully Completes Capital Raising
30/03/17PRICE SENSITIVE
ZLD Trading Halt
28/03/17PRICE SENSITIVE
ZLD Zelda Enters Strategic Partnership with CannPal
27/03/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
62.0¢ 		Change
0.050(8.77%) 		Mkt cap ! $7.716M
Open High Low Value Volume
59.0¢ 62.0¢ 59.0¢ $1.614K 2.679K

Buyers (Bids)

No. Vol. Price($)
1 868 59.0¢
 

Sellers (Offers)

Price($) Vol. No.
65.0¢ 41 1
View Market Depth
Last trade - 15.04pm 03/12/2024 (20 minute delay) ?
ZLD (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.